Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed Dec 6, 2021
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Award
Ordinary Shares
2021-12-02+340,000→ 507,258 total
Footnotes (1)
- [F1]On December 2, 2021, the reporting person was granted 340,000 RSUs. 240,000 RSUs are subject to service-based vesting conditions and the remaining 100,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.